Dashwood M R, Mehta D, Izzat M B, Timm M, Bryan A J, Angelini G D, Jeremy J Y
Department of Physiology, Royal Free Hospital School of Medicine, London, UK.
Atherosclerosis. 1998 Apr;137(2):233-42. doi: 10.1016/s0021-9150(97)00249-9.
Proliferation of vascular smooth muscle cells (VSMC) is a principal event in neointima formation in saphenous vein-coronary artery bypass grafts. Since endothelin-1 (ET-1) promotes VSMC replication and ET-1 receptor antagonists inhibit neointima formation in arterial injury models, it is reasonable to propose that ET-1 may be involved in neointima formation in vein grafts. However, it is not known what alterations of ET-1 and its receptors (if any) occur in vein grafts. The objective of this study, therefore, was to investigate the distribution of ET-1 and ET-1 receptor subtypes (ET(A) and ET(B)) in porcine vein grafts. Unilateral interposition saphenous vein grafting was performed by end to end anastomosis after excision of a segment of carotid artery in Landrace pigs. One month after surgery, vein grafts, ungrafted saphenous veins and carotid arteries were excised, ET-1 immunoreactivity identified by immunocytochemistry and ET(A) and ET(B) receptor subtypes studied using autoradiography. In vein grafts, there was a greater density of ET(A) compared to ET(B) receptors in both the tunica media and neointima. ET(A) binding in the tunica media of ungrafted saphenous vein was greater than that in the carotid artery or vein grafts, but greater in the vein graft compared to the carotid artery. Immunoreactive ET-1 was located in endothelial cells and throughout the neointima of the vein graft. Dense ET-1 binding (to both ET(A) and ET(B) receptors) was also associated with microvessels in the adventitia within the graft. In vein grafts, there was strong ET(B) binding to neutrophils which were present in high numbers at the subendothelium and within the adventitia. It is concluded ET(A) receptors may play a role in vein graft thickening at the medial and neointimal VSMC level, whereas ET(B) receptors may play a role in microangiogenesis. The higher levels of ET(A) receptors in the tunica media of ungrafted saphenous vein relative to the carotid artery and vein graft may also render this conduit susceptible to neointima formation. These data indicate that studies on the effect of ET receptor antagonists on the pathobiology of vein graft disease is warranted.
血管平滑肌细胞(VSMC)增殖是隐静脉 - 冠状动脉旁路移植术中新生内膜形成的主要事件。由于内皮素 - 1(ET - 1)可促进VSMC复制,且ET - 1受体拮抗剂在动脉损伤模型中可抑制新生内膜形成,因此有理由推测ET - 1可能参与了静脉移植物的新生内膜形成过程。然而,尚不清楚静脉移植物中ET - 1及其受体(若存在)会发生何种改变。因此,本研究的目的是调查ET - 1及ET - 1受体亚型(ET(A)和ET(B))在猪静脉移植物中的分布情况。在长白猪的一段颈动脉切除后,通过端端吻合术进行单侧间置隐静脉移植。术后1个月,切除静脉移植物、未移植的隐静脉和颈动脉,采用免疫细胞化学方法鉴定ET - 1免疫反应性,利用放射自显影技术研究ET(A)和ET(B)受体亚型。在静脉移植物中,中膜和新生内膜中ET(A)受体的密度均高于ET(B)受体。未移植隐静脉中膜的ET(A)结合力大于颈动脉或静脉移植物,但静脉移植物中的ET(A)结合力大于颈动脉。免疫反应性ET - 1定位于静脉移植物的内皮细胞及整个新生内膜。密集的ET - 1结合(与ET(A)和ET(B)受体均有关)也与移植物外膜中的微血管相关。在静脉移植物中,ET(B)与大量存在于内皮下和外膜中的中性粒细胞有强结合。结论是ET(A)受体可能在中膜和新生内膜VSMC水平的静脉移植物增厚中起作用,而ET(B)受体可能在微血管生成中起作用。未移植隐静脉中膜相对于颈动脉和静脉移植物的ET(A)受体水平较高,这也可能使该血管易于形成新生内膜。这些数据表明,有必要研究ET受体拮抗剂对静脉移植物疾病病理生物学的影响。